Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common heart drug cut COPD hospitalizations?

NCT ID NCT03566667

Disease control Sponsor: Ole Frobert, MD, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether adding the beta-blocker metoprolol to standard care can reduce a combined risk of death, COPD flare-ups, and heart-related hospitalizations in people with COPD who do not have known heart disease. About 1,700 adults with COPD will receive either metoprolol or usual care, and their outcomes will be tracked for one year. The goal is to see if this inexpensive drug can offer broader protection for COPD patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metoprolol, a beta-blocker, added to standard COPD care
What this could lead to
If it works, this could offer a low-cost way to reduce hospitalizations and deaths in people with COPD, even without heart disease.
What could go wrong
This is a pragmatic, unblinded trial, so results may be influenced by expectations. Metoprolol can cause side effects like low blood pressure or fatigue, and may not benefit all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

1,713 people

The number who actually took part.

Started

Jun 2018

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A diagnosis of COPD confirmed by spirometry showing post bronchodilator value of Forced Expiratory Volume in one second (FEV1)//Forced Vital Capacity (FVC) \< 70 according to the Global Initiative on Obstructive Pulmonary Disease (GOLD) * ≥40 years of age * Sinus rhythm ≥50/min and \<120 at inclusion Exclusion Criteria: * Known hypersensitivity to metoprolol or related derivatives * AV block II or III unless treated with a pacemaker * Sinus bradycardia (resting heart rate \<50/min) * Sick sinus syndrome unless treated with a pacemaker * Atrial fibrillation/flutter * Clinical signs of or a previous diagnosis of heart failure, angina pectoris, myocardial infarction, cerebrovascular disease or critical peripheral ischemia * Systolic blood pressure \<90 mmHg * Any tachy-arrythmias other than sinus rhythm * Sinus tachycardia \>120 / min * Systolic blood pressure \<90 mmHg * Severe bronchial asthma * Current beta-blocker treatment * Inability to provide informed consent * Age below 40 years * Acute on-going exacerbation of COPD * Previous randomization in the BRONCHIOLE trial * Ongoing pregnancy (excluded by pregnancy test in fertile women)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

Contacts and locations

Locations

  • University Hospital of Örebro

    Örebro, 701 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.